Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454647 | 0.83 | MAPT (0.53) | ALDH1A1NPC1RAB9AMAPTKDM4E | |
| SCHEMBL842153 | 0.83 | NPC1 (0.59) | ALDH1A1NPC1RAB9AHSD17B3TDP1 | |
| SCHEMBL862846 | 0.82 | HSD17B3 (0.58) | ESR2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL4447937 | 0.81 | MAPT (0.54) | ALDH1A1NPC1RAB9AMAPTGAA | |
| SCHEMBL863102 | 0.81 | ESR2 (0.59) | ESR2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL14735749 | 0.81 | NPC1 (0.58) | ESR2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL26036082 | 0.81 | TAS1R3 (0.43) | ESR2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL22778963 | 0.80 | ALDH1A1 (0.57) | ESR2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL9001430 | 0.79 | ESR1 (0.64) | ESR2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL28394787 | 0.78 | HSD17B3 (0.62) | ESR2ALDH1A1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651163-B1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | BIOCON LTD (IN) | 2015-03-04 | — | — | EP | disclosed |
| US-8143366-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2012-03-27 | — | — | US | disclosed |
| US-20100081782-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | EKWURIBE NNOCHIRI N | 2010-04-01 | — | — | US | disclosed |
| US-7625995-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2009-12-01 | — | — | US | disclosed |
| US-20080146778-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | BIOCON LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| EP-1651163-A4 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | BIOCON LTD (IN) | 2008-03-26 | — | — | EP | disclosed |
| US-7335751-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2008-02-26 | — | — | US | disclosed |
| US-20060167234-A1 | Aryl carbamate oligomers for hydroilyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2006-07-27 | — | — | US | disclosed |
| EP-1651163-A2 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | Nobex Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005016240-A2 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | NOBEX CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167234-A1 | Aryl carbamate oligomers for hydroilyzable prodrugs and prodrugs comprising same | ALK, OGFR, AOX1 | ESR2 2778/4885ALDH1A1 469/4885NPC1 1654/4885 |
| US-20080146778-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | ALK, AOX1, OGFR | ESR2 2881/4885ALDH1A1 539/4885NPC1 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.